FDA chief to depart after Trump signed off on ousting him

FDA Commissioner Resigns Following Trump’s Approval to Replace Him

FDA chief to depart after Trump – Food and Drug Administration (FDA) head Marty Makary has announced his exit from the Trump administration, according to three individuals with insider knowledge of the situation. The decision followed President Donald Trump’s endorsement of a strategy to remove Makary, as confirmed by a recent directive issued by the White House. Makary’s departure marks a significant shift in the leadership of the agency, which has been embroiled in frequent personnel changes and policy debates throughout his tenure.

Internal and External Pressures Fuel Resignation

Throughout his time in the role, Makary encountered persistent challenges from within the administration. His reluctance to endorse the sale of flavored e-cigarettes became a central point of contention, prompting direct intervention from Trump. This issue, along with other disagreements, led to a growing rift between Makary and the executive branch. Additionally, external groups such as pharmaceutical companies and anti-abortion organizations contributed to the pressure, criticizing his approach to regulatory decisions.

Senior ranks within the FDA saw continuous turnover, with several high-level officials leaving in recent months. This instability, combined with Makary’s resistance to certain policies, created an environment where his position became increasingly precarious. White House and Health and Human Services (HHS) officials had long debated the direction of the FDA, and Makary’s stance on flavored vaping products intensified these discussions.

Transition to Acting Leadership and Senate Role

Trump is anticipated to appoint Kyle Diamantas, the agency’s deputy commissioner responsible for food programs, as the interim FDA head. This choice aims to provide continuity as the administration seeks a permanent replacement. In a statement on Truth Social, Trump confirmed Makary’s resignation and his selection of Diamantas, signaling the end of the commissioner’s tenure.

Makary’s resignation creates another challenge for the HHS department, which already lacks permanent leadership for the Centers for Disease Control and Prevention (CDC) and the surgeon general. The process of appointing a new FDA commissioner will require Senate approval, potentially diverting attention from other pressing issues. Despite this, HHS Secretary Robert F. Kennedy Jr. expressed support for Makary’s work, stating:

“The search for a new Commissioner is already underway, and we will move forward with urgency.”

Flavored E-Cigarettes as Catalyst for Ouster

According to a source close to the situation, Makary’s exit was primarily driven by disputes over flavored e-cigarettes. The commissioner opposed the approval of youth-oriented flavors, believing they contributed to rising vaping rates among teenagers. However, his position was overruled by higher authorities within the administration, forcing him to comply with the decision. This conflict culminated in a direct confrontation with Trump, who voiced frustration over the FDA’s regulatory stance.

Just days before his resignation, Makary was scheduled to testify about the agency’s proposed budget before the Senate Appropriations Committee. The timing of his departure raises questions about the political motivations behind the move, as well as the implications for the upcoming legislative session. Politico was the first to report the news, highlighting the significance of the resignation in the broader context of Trump’s administration.

Administration’s Push for Change and Strategic Considerations

The effort to remove Makary accelerated in recent days, fueled by a faction of White House and HHS officials who grew frustrated with the FDA’s perceived chaos. These officials argued that Makary’s leadership had led to internal disagreements and inconsistent policy implementation, undermining the agency’s effectiveness. While some Trump aides cautioned against further destabilizing the health team, others viewed the change as necessary to align the FDA with the administration’s priorities.

One key factor in the decision was the desire to strengthen ties with influential groups, such as the anti-abortion movement and pharmaceutical industry. Makary’s resistance to certain regulations, including those affecting flavored vaping products, was seen as a barrier to these relationships. His allies, including former associates, were caught off guard by the suddenness of the move, as Makary had previously signaled optimism about retaining his position.

Legacy of Makary’s Tenure and Future Challenges

Since taking office in March 2025, Makary had aimed to streamline the FDA’s decision-making process, vowing to expedite approvals for drugs, devices, and vaccines. However, his efforts were frequently met with criticism, particularly from pharmaceutical companies dissatisfied with his management style and the outcomes of the drug review process. The FDA’s broader portfolio, which includes tobacco regulation, also became a source of controversy, as Makary’s approach clashed with expectations from various stakeholders.

Recent events, such as the reversal of FDA policy on flavored e-cigarettes, underscore the shifting dynamics within the agency. This decision, which followed intense internal debate, highlights the administration’s growing influence over regulatory choices. As the search for a new commissioner begins, the focus will likely remain on aligning the FDA with Trump’s vision for healthcare policy, including stronger support for the anti-abortion movement and a more industry-friendly approach to drug approvals.

The departure of Makary also reflects broader trends in the Trump administration’s management of federal agencies. With multiple high-level positions vacated, the White House faces the task of replacing key officials before the November elections. Critics argue that this rapid turnover may weaken the agency’s stability, but supporters contend it is a necessary step to ensure the FDA operates in line with the administration’s goals.

As the new acting commissioner takes the helm, the focus will shift to maintaining regulatory momentum and addressing ongoing debates about public health. The FDA’s role in shaping healthcare policy remains critical, and its next leader will need to navigate complex internal dynamics while responding to external pressures from industry and advocacy groups. With the Senate’s confirmation process looming, the administration’s ability to secure a permanent replacement will be a key test of its political strategy in the remaining months of the term.